[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370190-105":59,"doc-detail-370190-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-the-understanding-and-therapeutic-manipulation-of-cancer-immune-responsiveness-a-society-for-immunotherapy-of-cancer-sitc-review","Advances in the understanding and therapeutic manipulation of cancer immune responsiveness - a Society for Immunotherapy of Cancer (SITC) review","","Cancer immunotherapy, including immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT), has become a standard, potentially curative option for a subset of advanced solid and liquid tumors. Yet most patients do not benefit from rapidly evolving insights into cancer immune responsiveness (CIR). CIR depends on multiple patient-specific inherited and acquired factors plus intrinsic cancer cell biology. The review summarizes emerging concepts and discusses recent advances and novel strategies, emphasizing ICI and ACT.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-the-understanding-and-therapeutic-manipulation-of-cancer-immune-responsiveness-a-society-for-immunotherapy-of-cancer-sitc-review/370190/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-the-understanding-and-therapeutic-manipulation-of-cancer-immune-responsiveness-a-society-for-immunotherapy-of-cancer-sitc-review/370190.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are the two main cancer immunotherapy modalities emphasized in the review?","Question",{"text":112,"@type":113},"The review highlights immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT) as the two prominent modalities for understanding and therapeutically manipulating cancer immune responsiveness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why do most cancer patients not benefit from immunotherapy despite advances?",{"text":117,"@type":113},"Most patients do not receive benefits because the mechanisms determining cancer immune responsiveness are multifactorial and not fully understood, and many patient-specific and tumor-specific factors influence response.",{"name":119,"@type":110,"acceptedAnswer":120},"How might germline genetics influence antitumor immune responses?",{"text":121,"@type":113},"Genome-wide germline studies suggest that rare and common genetic variants can affect immunologic disorders, immune homeostasis, and infectious diseases, implying germline variants may influence antitumor immune responses, although their relative impact is hard to estimate.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370190,1790795655,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Open access Review  \nAdvances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer  \n(SITC) review  \nAlessandra Cesano,1 Ryan Augustin,2,3 Luigi Barrea,4 Davide Bedognetti,5 Tullia C Bruno,6 Alberto Carturan  ,7 Christian Hammer,8 Winson S Ho,9 Jakob Nikolas Kather,10 Tomas Kirchhoff,11 Rongze O Lu,12 Jennifer McQuade,13 Yana G Najjar  ,14 Violena Pietrobon,5 Marco Ruella  ,7 Rhine Shen,5  \nLaura Soldati,15 Christine Spencer,16 Allison Betof Warner  ,17 Sarah Warren  ,5 Elad Ziv,9 Francesco M Marincola18  \nTo cite: Cesano A, Augustin R, Barrea L, et al. Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review. Journal for ImmunoTherapy of Cancer 2025;13:e008876 . doi:10 . 1136/ jitc-2024-008876  \nAccepted 12 December 2024  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Francesco M Marincola; [fmarincola@sonatatx.com](fmarincola@sonatatx.com)  \nABSTRACT  \nCancer immunotherapy—including immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT)—has become a standard, potentially curative treatment for a subset of advanced solid and liquid tumors. However, most patients with cancer do not benefit from the rapidly evolving improvements in the understanding of principal mechanisms determining cancer immune responsiveness (CIR); including patient-specific genetically determined and acquired factors, as well as intrinsic cancer cell biology. Though CIR is multifactorial, fundamental concepts are emerging that should be considered for the design of novel therapeutic strategies and related clinical studies. Recent advancements as well as novel approaches to address the limitations of current treatments are discussed here, with a specific focus on ICI and ACT.   \nINTRODUCTION  \nImmunotherapy for cancer scored two “home runs” through the development of immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT) . These two modalities can offer long-term remission as well as a potential “cure” for cancers that are refractory to standard or alternate experimental therapies. Yet, most patients with cancer do not receive benefits from immunotherapy. While mechanisms determining cancer immune responsiveness (CIR) are gradually becoming more understood, much remains to be learned. Here, experts from the Society for Immunotherapy of Cancer’s (SITC) Cancer Immune Responsiveness Committee summarizes salient advancements in emerging areas spanning a broad range of factors related to inherited or acquired patient characteristics  \nand intrinsic cancer biology (figure 1) . We highlight advances in overcoming unmodifiable factors such as germline and somatic determinants of CIR as well as correcting modifiable factors related to the behavioral, environmental, and anamnestic environment of individual patients. The current status of clinical progress is presented with particular attention to the two prominent modalities, ICI and ACT, with the belief that much can be learned by studying large cohorts of patients undergoing clinical trials, or real-world datasets, given these therapies are now approved as standard of care.  \nUnmodifiable host factors: germline genetics  \nGenome-wide germline studies demonstrated the impact of rare and common genetic variants on immunologic disorders,1 immune homeostasis,2 and infectious diseases including COVID-19,3 and hepatitis C virus infection.4 Thus, it is plausible that germline variants might influence antitumor immune responses, although their relative weight is difficult to estimate due to the plurality of other contributing factors. Large sample sizes are usually required to identify the modest effects ofa single genetic variant. For instance, it is estimated that achievin","cbCaij5cm4EDoRvr","https://ap.wps.com/l/cbCaij5cm4EDoRvr","pdf",1914602,22,"English","# Abstract\n# Introduction\n## Unmodifiable host factors: germline genetics\n## Germline genetic variants and response to immunotherapy","[{\"question\":\"What are the two main cancer immunotherapy modalities emphasized in the review?\",\"answer\":\"The review highlights immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT) as the two prominent modalities for understanding and therapeutically manipulating cancer immune responsiveness.\"},{\"question\":\"Why do most cancer patients not benefit from immunotherapy despite advances?\",\"answer\":\"Most patients do not receive benefits because the mechanisms determining cancer immune responsiveness are multifactorial and not fully understood, and many patient-specific and tumor-specific factors influence response.\"},{\"question\":\"How might germline genetics influence antitumor immune responses?\",\"answer\":\"Genome-wide germline studies suggest that rare and common genetic variants can affect immunologic disorders, immune homeostasis, and infectious diseases, implying germline variants may influence antitumor immune responses, although their relative impact is hard to estimate.\"}]","Advances in the understanding and therapeutic manipulation of cancer immune responsiveness - a Society for Immunotherapy of Cancer (SITC) review | PDF",1790187235,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40574ab374412fbc8a24d9e0c57d9b01.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17305cd2dc07b512eb26fb6cbaedf62d.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b18a2fc4edabf6df09ac35d93eab23fb.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35810917dbe9f47242b214dd83f809bc.webp",980,1306]